| Date |
Event |
Presentation |
Speakers |
|
March 19, 2014
|
3rd Neurological Biomarkers
|
A post-GWAS Method for Translating Statistical Associations to Disease-relevant Pathways
|
Allen Roses
|
|
May 31, 2013
|
ASCO Annual Meeting 2013
|
Special Session
|
Catherine Wang
|
|
April 6, 2013
|
AACR Annual Meetings
|
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Targeting Epigenetics: An Epicenter of Oncology Drug Discovery? Chairperson: Ho Man Chan, Novartis Institutes for BioMedical Research, Cambridge, MA
|
Dashyant Dhanak
|
|
|
|
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Oncology Drug Discovery and Development: Combination Therapies Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC
|
Tona M Gilmer, Axel Hoos
|
|
February 10, 2013
|
7thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE: An Intensive Course on Translating Research into Drugs
|
Plenary: Repurposing Compounds for CNS Targets: Utilizing Translational Bioinformatics
|
Pankaj Agarwal
|
|
September 3, 2012
|
Ourense Conference on Imaging Mass Spectrometry
|
Observing Directly the Distribution of an Inhaled Domain Antibody in Healthy and Infected Mice by MALDI MS Imaging
|
Peter S. Marshall
|
|
February 26, 2011
|
Immunity in the Respiratory Tract: Challenges of the Lung Environment (X6)
|
Immunotherapy: Helping the Host | TLR4 Agonists Facilitate “Rapid Acting Vaccine” Against the Respiratory Tract Pathogen, Influenza A
|
Jory R. Baldridge
|
|
February 26, 2011
|
Mucosal Biology: A Fine Balance between Tolerance and Immunity (X5)
|
Immunity in Respiratory Tract (X6) | TLR4 Agonists Facilitate “Rapid Acting Vaccine” Against the Respiratory Tract Pathogen, Influenza A
|
Jory R. Baldridge
|
|
February 12, 2011
|
Cancer Control by Tumor Suppressors and Immune Effectors (J8)
|
Cancer Vaccines: Prophylaxy or Therapy | Development of the MAGE-A3 ASCI: From Tumor Specificity to Predictive Biomarkers
|
Vincent G Brichard
|
|
September 23, 2009
|
TRACK 4: Bridging Silos in Biomarker Development : Third Annual Biomarker Data Analysis
|
An Effective Framework for Omic Data Analysis
|
Jie J. Cheng
|
|
January 26, 2009
|
7th Annual Partnering with Central Labs
|
B1 : How to Reduce the Burden on Smaller Sponsor Clinical Team-The Cross Functional Approach
|
Karen Turner
|
|
March 30, 2008
|
Nuclear Receptors: Steroid Sisters
|
Drug Development
|
Dennis Sprecher
|
|
March 30, 2008
|
Nuclear Receptors: Orphan Brothers
|
Drug Development
|
Dennis Sprecher
|
|
March 25, 2008
|
RNAi, MicroRNA, and Non-Coding RNA
|
MicroRNAs and Their Targets (Plants and Invertebrates)
|
Eric C Lai
|
|
October 11, 2007
|
Compound Profiling & Chemogenomic Approaches to Drive Decision Making and Predict Clinical Adverse Effects (Oct 11-12)
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY (14:00-17:30)
|
Dana E. Vanderwall
|
|
|
|
SELECTING LEADS AND DETECTING ADVERSE ACTIVITY: Analysis of Biological Mechanism of Action, and Characterization of Profiles across the Progression Path (14:05-14:35)
|
Dana E. Vanderwall
|
How We Rank